Table 1 Published studies in the literature about ablative and radical radiotherapy in the management of oligometastases

Casamassine et al [84].

2011

71 patients:

No ADT

- 13 persistent regression

- 28 post-prostatectomy

- 15 post-radiotherapy

- 2 bone metastases

- 28 post-prostatectomy and radiotherapy

- 8 lymph node recurrences (outside the irradiated áreas)

Muacevic et al. [58].

2011

64 bone metastases

-19 ADT

95% local control

- Mean dose 20,2 Gy (range 16,6-22 Gy)

- 8 patients chemotherapy

Würschmidt et al. [83].

2011

26 patients

Mean dose 75,6 Gy (primary site) and 66,6 Gy (lymph node sites)

- Overall survival at 28 m: 94%

- Biochemical relapse free survival (primary site): 83%; 49% (recurrences)

- Distant free survival 100% (primary site) and 75% (recurrent)

Ahmed et al. [89].

2013

17 patients (21 lesions)

Mean dose 20 Gy in 1 to 3 fractions

- Local control rates 100%

- 2-5 year progresión-free survival 20%

Berkovic et al. [87].

2012

24 patients with biochemical relapse after initial treatment

- SBRT 50 Gy in 10 fractions

- 100% 2-year local control

- None ADT

-Progr. free survival at 2 years 42%

- ADT: median survival free 38 months

Jereczek-Fossa et al. [85].

2012

34 re-irradiated patients: 15 local relapse, 4 anastomosis, 16 nodal and

23 Gy in 3 fractions in lymph node metastases and 36 Gy in 3 fractions in bone.

- 32 biochemical response

- 4 PSA stabilization

3 distant metastases (2 retroperitoneal, 1 bone)

- 2 PSA progression

- 17 disease progression

- Progression free survival at 30 m: 42,6%.

Shick et al. [82].

2013

22 oligometastasic patients (55% one lesión)

55% ADT + EBRT (65 Gy)

- Biochemical relapse-free survival at 3 y: 63%

- Overall survival 89%

Picchio et al. [45].

2014

83 patients biochemical recurrence after radical primary treatment

No ADT

- 66 patients complete biochemical response

- 12 partial biochemical response

- 1 stable disease

- 15 progression disease